# Yemaachi Biotechnology **Source:** https://geo.sig.ai/brands/yemaachi-biotechnology **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** yemaachi.com **Last Updated:** 2026-04-14 ## Summary Precision oncology biotech developing African population-specific cancer diagnostics; $25M Cancer Grand Challenges award with Roche partnership on The African Cancer Atlas in Ghana. ## Company Overview Yemaachi Biotechnology is a precision oncology company applying immunogenomics, bioinformatics, and AI to develop cancer diagnostics and treatments specifically calibrated for African and African-descent populations — addressing the critical gap in oncology research where most cancer data and therapies have been developed on predominantly European-ancestry patient populations, leaving African patients underserved by current diagnostic tools and treatment protocols. Founded and backed by Y Combinator, Yemaachi is based in Accra, Ghana and has raised $29+ million including a $25 million Cancer Grand Challenges award and a $3 million seed round led by V8 Capital.\n\nYemaachi's research platform combines the collection of cancer genomics data from African patients (building one of the largest African cancer biobanks) with AI analysis to identify genomic variants, immune signatures, and biomarkers specific to African populations. This enables the development of diagnostic tests calibrated for African-specific tumor biology and the identification of therapeutic targets that may differ from European-ancestry cancer drivers. The company launched the Sheba HPV Test in Ghana (cervical cancer screening) and is partnering with Roche on The African Cancer Atlas — a comprehensive genomic characterization of cancer across Africa.\n\nIn 2025, Yemaachi operates at the intersection of oncology research, diagnostics, and population genomics for an underserved market. Cancer is a growing health crisis across sub-Saharan Africa, where late-stage diagnosis is the norm due to limited screening infrastructure and the poor sensitivity of Western-developed tests on African patients. Yemaachi's approach — building African-specific cancer intelligence — positions the company as both a research institution and a commercial diagnostics provider. The 2025 strategy focuses on expanding the African Cancer Atlas partnership with Roche, launching additional HPV and cancer screening products across West Africa, and partnering with global pharma companies seeking to include African populations in clinical trials. ## Frequently Asked Questions ### What is Yemaachi Biotechnology? Yemaachi Biotechnology is an Accra-based cancer research company founded in 2020 that uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to diversify precision cancer diagnostics and treatments with focus on African populations. The company is Y Combinator backed (S21) and has raised over $29M in total funding. ### What products and services does Yemaachi Biotechnology offer? Yemaachi offers cancer diagnostics, HPV testing (including the Sheba HPV Test), immunogenomics analysis, bioinformatics services, AI-driven research, precision oncology, genomic sequencing, cancer detection tools, treatment development, and research collaboration services. ### Who are Yemaachi Biotechnology's target customers? Yemaachi serves African healthcare systems, cancer patients, and global research institutions. The company specifically focuses on addressing cancer diagnostics and treatment needs for African populations. ### When was Yemaachi Biotechnology founded? Yemaachi Biotechnology was founded in 2020 and participated in Y Combinator's S21 batch. ### Where is Yemaachi Biotechnology located? Yemaachi Biotechnology is based in Accra, Ghana. ### How much funding has Yemaachi Biotechnology raised? Yemaachi has raised over $29M in total funding, including a $25M Cancer Grand Challenges award (up to over 5 years, March 2024), a $3M seed round in 2022 led by V8 Capital, and a $1M Bill and Melinda Gates Foundation grant. Investors include Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital, LifeLine Family Heritage Fund, and Ethan Perlstein. ### What are Yemaachi Biotechnology's key achievements? Key achievements include securing a $25M Cancer Grand Challenges award in March 2024, launching the Sheba HPV Test in Ghana in January 2025, receiving a Calestous Juma Science Leadership Fellowship from the Gates Foundation, and establishing partnerships with Roche for The African Cancer Atlas (TACA) and with Lucence for the AMBER Study on breast cancer genomics. ### What technology and approach does Yemaachi Biotechnology use? Yemaachi uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to develop precision cancer diagnostics and treatments. Their approach focuses specifically on diversifying cancer research and care for African populations. ### How can I access Yemaachi Biotechnology's services? Based on the provided information, Yemaachi serves African healthcare systems and collaborates with global research institutions. Contact information was not provided in the company details. ### What are Yemaachi Biotechnology's recent developments? Recent developments include the January 2025 launch of the Sheba HPV Test in Ghana, the March 2024 Cancer Grand Challenges award of $25M, and ongoing collaborations with Roche on The African Cancer Atlas (TACA) and with Lucence on the AMBER Study for breast cancer genomics in women of African descent. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*